A Study Comparing of Two Different Chemotherapy Regimens, in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00606021
First received: January 17, 2008
Last updated: November 21, 2011
Last verified: November 2011
  Purpose

This is a multicenter, open-label, randomized, two-arm Phase 2 study comparing pemetrexed plus best supportive care with best supportive care alone as maintenance therapy following first-line treatment with a pemetrexed-cisplatin combination in patients with advanced non-squamous non-small cell lung cancer.

A total of approximately 100 patients are planned to be enrolled, and following completion of four cycles of pemetrexed-cisplatin (Induction Phase) those patients in which disease progression has not occurred will be randomized in a 2:1 ratio to one of two treatment arms (Maintenance Phase): Arm A (pemetrexed plus best supportive care) or Arm B (best supportive care alone).


Condition Intervention Phase
Non Small Cell Lung Cancer
Drug: pemetrexed
Drug: Best Supportive Care
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized Phase 2 Study Comparing Pemetrexed Plus Best Supportive Care With Best Supportive Care as Maintenance, Following First-Line Treatment With Pemetrexed-Cisplatin, in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

Resource links provided by NLM:


Further study details as provided by Eli Lilly and Company:

Primary Outcome Measures:
  • Progression Free Survival During Maintenance Phase [ Time Frame: Randomization to progression of disease (PD) or date of death from any cause up to 30.9 months ] [ Designated as safety issue: No ]
    Progression free survival is defined as the time from randomization until the date of progression of disease (PD) or death from any cause. PD was determined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD is ≥20% increase in sum of longest diameter of target lesions. PD in maintenance phase uses the last lesion assessment prior to randomization as the baseline assessment.


Secondary Outcome Measures:
  • Progression Free Survival During Overall Period (Induction Phase [IP] + Maintenance Phase [MP]) [ Time Frame: First dose of study drug during IP to PD or date of death from any cause up to 33.6 months ] [ Designated as safety issue: No ]
    Progression-free survival in overall period is defined as the time from the date of first dose of study drug during IP until the date of PD or death from any cause. PD was determined using RECIST criteria. PD is ≥20% increase in sum of longest diameter of target lesions. PD in overall period uses the screening lesion assessment prior to the induction phase as the baseline assessment.

  • Overall Survival During Maintenance Phase [ Time Frame: Randomization to PD or date of death from any cause up to 31.3 months ] [ Designated as safety issue: No ]
    Overall survival in maintenance phase is defined as the time from randomization to death. Participants who were alive were censored at the last contact.

  • Overall Survival During Overall Period (IP + MP) [ Time Frame: First dose of study drug during IP to PD or date of death from any cause up to 34.1 months ] [ Designated as safety issue: No ]
    Overall survival in overall period is defined as the time from first dose of study drug during IP to death. Participants who were alive were censored at the last contact.

  • Number of Participants With Adverse Events (AEs) During Overall Period [ Time Frame: First dose of study drug during IP through overall study completion (up to 34.3) months ] [ Designated as safety issue: Yes ]
    The list of serious adverse events (SAEs) and other non-serious adverse events (AEs) are in Adverse Events Section.

  • Tumor Response Rate and Disease Control Rate After Induction Phase (IP) [ Time Frame: Randomization to measured PD up to 31.4 months ] [ Designated as safety issue: No ]
    Tumor response rate (%) is the number of responders (participants with best response of CR or PR) divided by the number of participants qualified for tumor response according to RECIST criteria multiplied by 100. Disease control rate is percentage of participants with a best response of stable disease [SD], PR, or CR. CR=disappearance of all target lesions; PR=30% decrease in sum of longest diameter of target lesions; PD is≥20% increase in sum of longest diameter of target lesions. SD= neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.


Enrollment: 106
Study Start Date: January 2008
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A: Pemetrexed + Best Supportive Care

Pemetrexed: 500 milligrams per square meter (mg/m²) , intravenous (IV), Day 1 of each 21-day cycle for 6 cycles

Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.

Drug: pemetrexed
500 mg/m², IV, Day 1 of each 21-day cycle for 6 cycles
Other Names:
  • Alimta
  • LY231514
Drug: Best Supportive Care
Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
Active Comparator: B: Best Supportive Care
Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
Drug: Best Supportive Care
Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  1. You must be at least 18 years old
  2. You must have been diagnosed with non-squamous non-small cell lung cancer (NSCLC)
  3. You must have had no prior systemic anticancer therapy for lung cancer
  4. You must live close enough to the study doctor to be able to visit regularly for follow up
  5. You must have signed informed consent form indicating your willingness to take part in this study
  6. Your laboratory and medical history and tests must meet study requirements

Exclusion criteria:

  1. Treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry
  2. Prior radiotherapy and surgery should be completed at least 4 weeks prior to initiation of treatment
  3. Serious concomitant systemic disorder (e.g., active infection including human immunodeficiency virus, or unstable cardiovascular disease)
  4. Prior malignancy other than NSCLC, carcinoma in situ of the cervix, or nonmelanoma skin cancer unless treated at least 5 years previously with no subsequent evidence of recurrence
  5. Brain metastasis
  6. Presence of clinically significant (by physical exam) third-space fluid collections, for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry
  7. Significant weight loss (greater than 10%), over the previous 6 weeks before study entry
  8. Concurrent administration of any other antitumor therapy
  9. Inability to interrupt aspirin or other non-steroidal anti-inflammatory agents for a 5-day period (8-day period for long-acting agents such as piroxicam)
  10. Inability or unwillingness to take folic acid, dexamethasone (or equivalent) or vitamin B12 supplementation
  11. Pregnancy or breast-feeding
  12. You are allergic to pemetrexed
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00606021

Locations
Egypt
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Assiut, Egypt, 0000
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Cairo, Egypt, 11372
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Mounofia, Egypt, 32514
Lebanon
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Beirut, Lebanon
Saudi Arabia
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Riyadh, Saudi Arabia, 11211
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9am to 5pm Eastern Time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
  More Information

Additional Information:
No publications provided by Eli Lilly and Company

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT00606021     History of Changes
Other Study ID Numbers: 11839, H3E-EZ-S114
Study First Received: January 17, 2008
Results First Received: October 3, 2011
Last Updated: November 21, 2011
Health Authority: Egypt: Ministry of Health and Population
Saudi Arabia: Research Advisory Council
Lebanon: Institutional Review Board

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Carcinoma, Bronchogenic
Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Pemetrexed
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Folic Acid Antagonists
Antimetabolites, Antineoplastic
Antimetabolites

ClinicalTrials.gov processed this record on July 28, 2014